A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

Trial Details

NCT ID
NCT05498428
Phase
PHASE2
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Amivantamab
  • Lazertinib
  • Carboplatin
  • Pemetrexed
  • Direct Oral Anticoagulant (DOAC)
  • Low Molecular Weight Heparin (LMWH)
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Orange, California, United States|33.78779,-117.85311
  • Stanford, California, United States|37.42411,-122.16608
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Boca Raton, Florida, United States|26.35869,-80.0831

Key Eligibility Criteria

  • Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not ame…
  • All cohorts except Cohort 4: Participants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST…
  • May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere w…
  • Have adequate organ (renal, hepatic, hematological, coagulation and cardiac) functions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →